Platelets News and Research RSS Feed - Platelets News and Research

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. [More]
FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults. [More]
New scientific conference 'Aspirin in the 21st Century' to be held in London

New scientific conference 'Aspirin in the 21st Century' to be held in London

What more can be said about aspirin, a medicine that was first prescribed at the end of the 19th century? It is known and accepted in every country. For over a hundred years it has been the standard by which all other, newer, painkillers have had to be judged, and it has never been found to be inferior. It is still considered the world's leading analgesic. [More]
New study uses donor sample to evaluate how self-identification measures intersect with genetics

New study uses donor sample to evaluate how self-identification measures intersect with genetics

For years, medicine has relied on self-reported race/ethnicity as the basis of an array of decisions, from risk for disease to matching organ donors. Now, a study led by researchers at UC San Francisco has found that when that information matters most - in connecting bone marrow donors to patients - the format of the questions may determine how well the answers actually correspond to their genes. [More]
Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain. [More]
Breakdown of fibrin protein essential for bone fracture repair

Breakdown of fibrin protein essential for bone fracture repair

A team of Vanderbilt investigators has discovered that fibrin, a protein that was thought to play a key role in fracture healing, is not required. Instead, the breakdown of fibrin is essential for fracture repair. [More]
Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

Mount Sinai launches clinical trial to test effectiveness of ticagrelor drug in treating coronary stent patients

The Icahn School of Medicine at Mount Sinai has launched an international clinical trial called TWILIGHT to test the safety and effectiveness of treating coronary stent patients with the anti-clotting medication ticagrelor alone, instead of combining it with aspirin, which is the current standard of care. Researchers will analyze the potential benefits of administering ticagrelor to reduce clotting while at the same time reducing the risk of bleeding associated with the use of both medications. [More]
New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

New VA study demonstrates cardiovascular benefits of testosterone replacement therapy

A Veterans Affairs database study of more than 83,000 patients found that men whose low testosterone was restored to normal through gels, patches, or injections had a lower risk of heart attack, stroke, or death from any cause, versus similar men who were not treated. [More]
Engineered protein shown effective in patients with severe von Willebrand disease

Engineered protein shown effective in patients with severe von Willebrand disease

The first protein engineered to help control bleeding episodes in patients with severe von Willebrand disease (vW disease) has been shown to be safe and effective, according to results of a Phase III trial. [More]
New study reveals protein's critical role in development and progression of AML

New study reveals protein's critical role in development and progression of AML

A new study by researchers at University of California, San Diego School of Medicine reveals a protein's critical - and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer. [More]
New study may help identify novel ways to treat immune thrombocytopenia

New study may help identify novel ways to treat immune thrombocytopenia

Immune thrombocytopenia, or ITP, is an autoimmune disease whereby the immune system sends antibodies to attack and destroy the body's platelets--blood cells responsible for controlling bleeding. [More]
IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. [More]
NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

NIBIB-supported researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury or in individuals with impaired clotting due to an inherited condition or as a result of certain medications or chemotherapy. [More]
UCSF scientists identify characteristics of progenitor cells

UCSF scientists identify characteristics of progenitor cells

University of California San Francisco scientists have identified characteristics of a family of daughter cells, called MPPs, which are the first to arise from stem cells within bone marrow that generate the entire blood system. The researchers said the discovery raises the possibility that, by manipulating the fates of MPPs or parent stem cells, medical researchers could one day help overcome imbalances and deficiencies that can arise in the blood system due to aging or in patients with specific types of leukemia. [More]
Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Researchers track down key gene mutation responsible for causing acute lymphoblastic leukemia

Two medical researchers from the Children's Hospital of Michigan and the Wayne State University School of Medicine have published the results of a nearly 10-year investigation that identified a key gene mutation that can trigger acute lymphoblastic leukemia, or ALL, and several other types of cancer. [More]
Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

Combination of tosedostat and LDAC results in overall response rate of 54% in elderly patients with AML

CTI BioPharma Corp. today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome (MDS). Results showed the combination of tosedostat with low dose cytarabine/Ara-C (LDAC) resulted in an overall response rate (ORR) of 54 percent in elderly patients with AML – with 45 percent of patients achieving durable complete responses (CR). [More]
Researchers show how a new drug speeds tissue regeneration in animal models

Researchers show how a new drug speeds tissue regeneration in animal models

The concept sounds like the stuff of science fiction: take a pill, and suddenly new tissues grow to replace damaged ones. Researchers at Case Western Reserve and UT Southwestern Medical Center this week announced that they have taken significant steps toward turning this once-improbable idea into a vivid reality. [More]

Blood research could improve treatment for injured soldiers on the battlefield

Blood research conducted by biomedical engineers from The University of Texas at San Antonio College of Engineering, in collaboration with the Blood Research Program of the U.S. Army Institute of Surgical Research, could change the way injured soldiers are treated on the battlefield. [More]
LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

Blood clots often form when lipid-rich plaques on the inner surface of arteries rupture and platelets aggregate at the site of injury. Cardiologists from Ludwig-Maximilians-Universitaet in Munich have now compared the effects of two new platelet aggregation inhibitors. [More]
Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen. [More]
Advertisement